At the news
? NEUTRALIMPACT 4/10 SC 13G filed Nov 9, 2026 at 20:40 ET
Goldman Sachs Group disclosed a 5.9% passive stake in Tandem Diabetes Care as of September 30, 2026, holding approximately 4.09 million shares. This is a new 13G filing by Goldman Sachs, which had not previously reported a 5%+ position in TNDM. The filing comes shortly after Tandem's Q3 2026 earnings beat consensus estimates, with revenue up 14% YoY and a narrower operating loss.
- Goldman Sachs Group reported beneficial ownership of 4,091,935 shares of Tandem Diabetes Care common stock, representing 5.9% of shares outstanding as of September 30, 2026.
- The filing is a Schedule 13G, certifying passive intent with no purpose or effect of changing or influencing control of the issuer.
- Goldman Sachs & Co. LLC, a registered broker-dealer and investment adviser, is the direct holder; Goldman Sachs Group is the parent holding company.
- This is a new 13G filing by Goldman Sachs; no prior 13G or 13D from this filer appears in the cross-filing context.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access